CD19 and B-cell chronic lymphocytic leukemia: In order to understand why only 26% of CLL patients benefited from CD19 CAR-T therapy while over 90% of CD19-positive B-ALL experienced CR, a detailed transcriptomic analysis was performed to compare T cells from CLL responders and non-responders post CD19 CAR-T therapy.